Avantor, Inc. - Understand $avtr stock

$AVTR Market Cap: $14.42 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$6.820B

TTM

Gross Margin

33.54%

TTM

Net Earnings

$309.6M

TTM

Current Assets

$2.505B

Q3 2024

Current Liabilities

$1.630B

Q3 2024

Current Ratio

153.68%

Q3 2024

Total Assets

$12.84B

Q3 2024

Total Liabilities

$7.287B

Q3 2024

Book Value

$5.553B

Q3 2024

Cash

$285.3M

Q3 2024

P/E

46.58

Nov 29, 2024 EST

Free Cash Flow

$747.2M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$6.967B	$7.512B	$7.386B	$6.394B	$6.040B	$5.864B	$1.247B	$691.3M
YoY Change	-7.26%	1.71%	15.52%	5.85%	3.0%	370.12%	80.44%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$6.967B	$7.512B	$7.386B	$6.394B	$6.040B	$5.864B	$1.247B	$691.3M
Cost Of Revenue	$4.603B	$4.910B	$4.883B	$4.313B	$4.120B	$4.045B	$814.6M	$371.6M
Gross Profit	$2.364B	$2.603B	$2.503B	$2.081B	$1.921B	$1.820B	$432.8M	$319.7M
Gross Profit Margin	33.93%	34.65%	33.88%	32.54%	31.8%	31.03%	34.7%	46.25%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$1.507B	$1.473B	$1.531B	$1.374B	$1.369B	$1.405B	$449.7M	$270.4M
YoY Change	2.31%	-3.78%	11.41%	0.35%	-2.59%	212.5%	66.31%
% of Gross Profit	63.74%	56.58%	61.15%	66.03%	71.27%	77.22%	103.9%	84.58%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$94.60M	$87.20M	$88.40M	$87.90M	$86.60M	$83.30M	$34.00M	$60.30M
YoY Change	8.49%	-1.36%	0.57%	1.5%	3.96%	145.0%	-43.62%
% of Gross Profit	4.0%	3.35%	3.53%	4.22%	4.51%	4.58%	7.86%	18.86%
Operating Expenses	$1.507B	$1.473B	$1.531B	$1.374B	$1.369B	$1.405B	$449.7M	$270.4M
YoY Change	2.31%	-3.78%	11.41%	0.35%	-2.59%	212.5%	66.31%
Operating Profit	$696.4M	$1.130B	$972.2M	$706.8M	$551.8M	$413.5M	-$210.4M	$49.30M
YoY Change	-38.38%	16.25%	37.55%	28.09%	33.45%	-296.53%	-526.77%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$284.8M	$265.8M	$217.4M	$307.6M	$440.0M	$523.8M	$200.9M	-$80.70M
YoY Change	7.15%	22.26%	-29.32%	-30.09%	-16.0%	160.73%	-348.95%
% of Operating Profit	40.9%	23.52%	22.36%	43.52%	79.74%	126.67%		-163.69%
Other Income/Expense, Net	$5.800M	-$800.0K	$10.60M	$9.900M	$2.500M	-$3.500M	$7.500M	$200.0K
YoY Change	-825.0%	-107.55%	7.07%	296.0%	-171.43%	-146.67%	3650.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	$410.5M	$851.1M	$753.0M	$62.30M	$40.60M	-$78.40M	-$441.8M	-$70.60M
YoY Change	-51.77%	13.03%	1108.67%	53.45%	-151.79%	-82.25%	525.78%
Income Tax	$89.40M	$164.6M	$180.4M	-$54.30M	$2.800M	-$26.90M	-$314.9M	$10.10M
% Of Pretax Income	21.78%	19.34%	23.96%	-87.16%	6.9%
Net Earnings	$321.1M	$686.5M	$572.6M	$116.6M	$37.80M	-$86.90M	-$112.7M	-$42.40M
YoY Change	-53.23%	19.89%	391.08%	208.47%	-143.5%	-22.89%	165.8%
Net Earnings / Revenue	4.61%	9.14%	7.75%	1.82%	0.63%	-1.48%	-9.03%	-6.13%
Basic Earnings Per Share	$0.48	$1.02	$0.86	$0.09	-$0.84	-$2.69
Diluted Earnings Per Share	$0.47	$1.01	$0.85	$0.09	-$0.84	-$2.69	-$210.9K	-$79.36K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$262.9M	$372.9M	$301.7M	$287.0M	$187.0M	$185.0M	$185.0M
YoY Change	-29.5%	23.6%	5.12%	53.48%	1.08%	0.0%
Cash & Equivalents	$262.9M	$372.9M	$301.7M	$287.0M	$187.0M	$185.0M	$185.0M
Short-Term Investments
Other Short-Term Assets	$143.7M	$153.1M	$81.40M	$91.00M	$135.0M	$100.0M	$78.00M
YoY Change	-6.14%	88.08%	-10.55%	-32.59%	35.0%	28.21%
Inventory	$828.1M	$913.5M	$872.0M	$740.0M	$711.0M	$671.0M	$695.0M
Prepaid Expenses
Receivables	$1.150B	$1.218B	$1.222B	$1.113B	$989.0M	$944.0M	$875.0M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.385B	$2.658B	$2.477B	$2.231B	$2.022B	$1.900B	$1.834B
YoY Change	-10.27%	7.29%	11.04%	10.34%	6.42%	3.6%
Property, Plant & Equipment	$858.2M	$845.7M	$813.3M	$675.0M	$689.0M	$599.0M	$664.0M
YoY Change	1.48%	3.98%	20.49%	-2.03%	15.03%	-9.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$237.6M	$174.8M	$125.3M	$91.00M	$73.00M	$63.00M	$113.0M
YoY Change	35.93%	39.51%	37.69%	24.66%	15.87%	-44.25%
Total Long-Term Assets	$10.59B	$10.81B	$11.42B	$7.676B	$7.751B	$8.012B	$8.613B
YoY Change	-2.02%	-5.37%	48.78%	-0.97%	-3.26%	-6.98%
Total Assets	$12.97B	$13.46B	$13.90B	$9.907B	$9.773B	$9.912B	$10.45B
YoY Change
Accounts Payable	$625.9M	$758.2M	$755.1M	$679.0M	$560.0M	$557.0M	$542.0M
YoY Change	-17.45%	0.41%	11.21%	21.25%	0.54%	2.77%
Accrued Expenses	$219.5M	$207.9M	$283.6M	$258.0M	$222.0M	$222.0M	$258.0M
YoY Change	5.58%	-26.69%	9.92%	16.22%	0.0%	-13.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$259.9M	$364.2M	$45.20M	$26.00M	$94.00M	$142.0M	$109.0M
YoY Change	-28.64%	705.75%	73.85%	-72.34%	-33.8%	30.28%
Total Short-Term Liabilities	$1.480B	$1.659B	$1.451B	$1.243B	$1.075B	$1.096B	$1.104B
YoY Change	-10.76%	14.34%	16.72%	15.63%	-1.92%	-0.72%
Long-Term Debt	$5.277B	$5.923B	$6.978B	$4.868B	$5.023B	$6.782B	$7.009B
YoY Change	-10.92%	-15.11%	43.34%	-3.09%	-25.94%	-3.24%
Other Long-Term Liabilities	$350.3M	$295.4M	$358.4M	$398.0M	$428.0M	$318.0M	$313.0M
YoY Change	18.58%	-17.58%	-9.95%	-7.01%	34.59%	1.6%
Total Long-Term Liabilities	$5.627B	$6.219B	$7.336B	$5.266B	$5.451B	$7.100B	$7.322B
YoY Change	-9.51%	-15.23%	39.32%	-3.39%	-23.23%	-3.03%
Total Liabilities	$7.720B	$8.609B	$9.700B	$7.232B	$7.311B	$9.104B	$9.477B
YoY Change	-10.32%	-11.25%	34.13%	-1.08%	-19.69%	-3.94%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018
Basic Shares Outstanding	675.6M shares	650.9M shares	590.5M shares	576.3M shares	401.2M shares	132.7M shares
Diluted Shares Outstanding	678.4M shares	679.4M shares	599.6M shares	583.4M shares	401.2M shares	132.7M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $14.422 Billion

About Avantor, Inc.

Avantor, Inc. engages in providing mission critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company is headquartered in Radnor, Pennsylvania and currently employs 14,500 full-time employees. The company went IPO on 2019-05-17. Its segments include Laboratory Solutions and Bioscience Production. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits, and peristaltic pumps. Equipment and instrumentation include filtration systems, virus inactivation systems, analytical instruments, freezers, and biological safety cabinets. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

Industry: Laboratory Analytical Instruments Peers: BIO-RAD LABORATORIES, INC. BIO-TECHNE Corp CHARLES RIVER LABORATORIES INTERNATIONAL, INC. REVVITY, INC. ILLUMINA, INC. METTLER TOLEDO INTERNATIONAL INC/ REPLIGEN CORP THERMO FISHER SCIENTIFIC INC. WEST PHARMACEUTICAL SERVICES INC WATERS CORP /DE/